Inhalation therapy education and training programs

Autor: Collins Vj

Publikováno v: JAMA: The Journal of the American Medical Association. 207:329-332

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::675ab2ab042dd0cbeb6a15a83b48c4da
https://doi.org/10.1001/jama.207.2.329

INTRODUCTION

Autor: Collins Vj

Publikováno v: Annals of the New York Academy of Sciences. 66:843-843

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bbd672e008b73389b805c9fc53ae92dc
https://doi.org/10.1111/j.1749-6632.1957.tb40772.x

Treatment with novel topoisomerase inhibitors in Ewing sarcoma models reveals heterogeneity of tumor response.

Autor: Lee U; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Szabova L; Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, United States., Collins VJ; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Gordon M; Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, United States., Johnson K; Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, United States., Householder D; Center for Advanced Preclinical Research, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, United States., Jorgensen S; Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, United States., Lu L; Center for Advanced Preclinical Research, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, United States., Bassel L; Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, United States., Elloumi F; Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Peer CJ; Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Nelson AE; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Varriano S; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Varma S; Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Roberts RD; Center for Childhood Cancer Research, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH, United States.; Department of Hematology, Oncology and Bone Marrow Transplant, Nationwide Children's Hospital, Columbus, OH, United States., Ohler ZW; Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, United States., Figg WD; Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Sharan SK; Center for Advanced Preclinical Research, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, United States., Pommier Y; Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Heske CM; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.

Publikováno v: Frontiers in cell and developmental biology [Front Cell Dev Biol] 2024 Oct 24; Vol. 12, pp. 1462840. Date of Electronic Publication: 2024 Oct 24 (Print Publication: 2024).

Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models.

Autor: McKay-Corkum GB; Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland., Collins VJ; Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland., Yeung C; Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland., Ito T; Urologic Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland., Issaq SH; Urologic Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland., Holland D; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health (NIH), Bethesda, Maryland., Vulikh K; Molecular Histopathology Lab, Frederick National Laboratory for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland., Zhang Y; National Clinical Target Validation Laboratory, Frederick National Laboratory for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland., Lee U; Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland., Lei H; Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland., Mendoza A; Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland., Shern JF; Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland., Yohe ME; Laboratory of Cell and Developmental Signaling, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland., Yamamoto K; Radiation Biology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland., Wilson K; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health (NIH), Bethesda, Maryland., Ji J; National Clinical Target Validation Laboratory, Frederick National Laboratory for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland., Karim BO; Molecular Histopathology Lab, Frederick National Laboratory for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland., Thomas CJ; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health (NIH), Bethesda, Maryland., Krishna MC; Radiation Biology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland., Neckers LM; Urologic Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland., Heske CM; Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Nov 01; Vol. 29 (21), pp. 4479-4491.

Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) with OT-82 induces DNA damage, cell death, and suppression of tumor growth in preclinical models of Ewing sarcoma.

Autor: Gibson AE; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Yeung C; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Issaq SH; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Collins VJ; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Gouzoulis M; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Zhang Y; National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Ji J; National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Mendoza A; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Heske CM; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Christine.heske@nih.gov.

Publikováno v: Oncogenesis [Oncogenesis] 2020 Sep 10; Vol. 9 (9), pp. 80. Date of Electronic Publication: 2020 Sep 10.